A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Purpose
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
Condition
- Migraine
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Be a male or female, age 18 to 75 years, inclusive, at the time of signing informed consent. 2. Has greater than a one-year history of migraine with or without aura as defined by International Headache Society criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated. 3. Has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the 2 months prior to screening (Visit 1). 4. Meet the following requirements: a. Is a male OR b. Is a female who is of non-childbearing potential defined by at least one of the following criteria: i. Postmenopausal as defined by one of the following: 1. A minimum of 12 months of spontaneous amenorrhea or 2. A minimum of 6 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone level > 40 mIU/mL or 3. At least 6 weeks post bilateral oophorectomy (with or without hysterectomy). OR ii. Post hysterectomy or bilateral salpingectomy, based on the participant's recall of their medical history OR c. Is a female of reproductive potential and: i. Agrees to remain abstinent from heterosexual activity OR ii. Agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the End of Study visit. Acceptable methods of birth control are: 1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal). 2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral; injectable; or implantable). 3. Intrauterine device (IUD); 4. Intrauterine hormone-releasing system (IUS); 5. Bilateral tubal occlusion; 6. Vasectomized partner; 7. Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action; 8. Male or female condom with or without spermicide; 9. Cap, diaphragm or sponge with spermicide; a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods). 5. Voluntarily agrees to participate in the study by giving written informed consent. 6. Is able to read, understand and complete the study questionnaires and eDiary. 7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions. 8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.
Exclusion Criteria
Participants are excluded from the trial if any of the following criteria apply: 1. Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the trial. Migraine history-related 2. Has difficulty distinguishing his/her migraine attacks from tension-type headaches. 3. Has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours. 4. Has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the 3 months prior to screening (Visit 1). 5. Has brainstem (also known as basilar-type) or hemiplegic migraine headache, or retinal migraine. 6. Was >50 years old at age of first migraine onset. 7. Is taking migraine prophylactic medication where the prescribed dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening. Medical history related 8. Has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia, or significant neurological disorders other than migraine [Patients who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study]. 9. Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Patients must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months. 10. Has a recent history (within the past 3 years of the screening visit) or current diagnosis or evidence of endocrine, hematological, immunological (including Sjogren's syndrome), renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases or hepatic impairment that, per the investigator's judgement, may jeopardize the subject's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results. 11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care. 12. Has a history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Patients with myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke or transient ischemic attack during the 6 months prior to screening. 13. Has a history of human immunodeficiency virus disease. 14. Has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption. Laboratory, vital sign, and electrocardiogram related 15. Has a positive test result at screening for hepatitis B surface antigen, hepatitis C virus antibody. 16. Has a screening estimated glomerular filtration rate estimated with the Modification of Diet in Renal Disease (MDRD) equation of <30 mL/min/1.73 m2. 17. Has a screening result for alanine aminotransferase or aspartate aminotransferase of >2.0 X upper limit of normal (ULN) or total bilirubin >1.5 X ULN at the Screening visit. Note: An isolated bilirubin >1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin is within the laboratory normal range. 18. Has a mean value for triplicate corrected QT interval to Fridericia's formula (QTcF) >450 ms for males and >470 ms for females at screening. 19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure >95 mmHg measured after at least 5 minutes at rest at the Screening Visit. Note: If a participant's blood pressure is exclusionary on the first triplicate assessment at the Screening Visit, they may have one repeat triplicate blood pressure assessment at that visit after another rest of at least 10 minutes. Medication use and substance abuse related 20. Has known history of or suspected abuse of alcohol or recreational drugs at Screening. 21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol [THC] or cannabidiol [CBD] within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening. 22. Has a positive drug screen at screening. Note: 1. If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g., for insomnia) and confirmatory documentation is obtained from the prescribing physician. 2. If amphetamines are detected on the drug screen, this is not exclusionary if the participant is taking a stimulant medication for a therapeutic purpose (e.g., Adderall for attention deficit hyperactivity disorder), confirmatory documentation is obtained from the prescribing physician, and the stimulant medication in question is known to be detected as amphetamine on the drug screen being used. 23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation (detailed in the protocol). 24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation. 25. Has a history of use of ergotamine medications ≥10 days per month on a regular basis for ≥3 months prior to screening. 26. Has a history of non-narcotic analgesic intake ≥15 days per month for - 3 months prior to screening. Other 27. Has known or suspected hypersensitivity to trial product(s) or related products. 28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food. 29. Has any surgery scheduled for the duration of the trial. 30. Has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females) or has a known hemoglobinopathy (e.g., sickle cell anemia, hemolytic anemia). 31. Has previous participation in this trial. Participation is defined as signed informed consent. 32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g., antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening or ever signed an informed consent for Study K-304 P004. Note: Patients may not be screened at more than one trial site for this study. 33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results. 34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Elismetrep 10 mg |
|
|
|
Experimental Elismetrep 20 mg |
|
|
|
Placebo Comparator Placebo |
|
Recruiting Locations
Birmingham, Alabama 35205
(205) 327-1077
Mobile, Alabama 36608
(251) 901-2127
Chandler, Arizona 85286
(623) 267-8314
Little Rock, Arkansas 72205
(501) 480-5088
Colton, California 92324
(909) 824-2325
Culver City, California 90230
(424) 227-8127
Encino, California 91316
(818) 578-4555
Irvine, California 92604
(909) 824-2325
Los Angeles, California 90017
(213) 261-3680
Los Angeles, California 90048
(323) 879-9999
Mission Viejo, California 92691
(949) 752-7910
Oceanside, California 92056
(760) 758-2222
Pomona, California 91767
(909) 981-5321
Pomona, California 91767
(909) 982-2719
Riverside, California 92503
(855) 367-8834
San Diego, California 92120
(855) 367-8834
Sherman Oaks, California 91403
(818) 990-2671
Spring Valley, California 91978
(619) 660-9068
Walnut Creek, California 94596
(925) 298-5147
Walnut Creek, California 94598
(925) 930-7267
West Covina, California 91790
(657) 230-7120
West Hills, California 91307
(818) 253-8966
Centennial, Colorado 80112
(303) 771-9000
Colorado Springs, Colorado 80910
(719) 634-6576
Fort Collins, Colorado 80528
(970) 226-6111
Waterbury, Connecticut 06708
(203) 419-4404
Atlanta, Georgia 30329
(770) 417-4454
Marietta, Georgia 30060
(678) 581-5252
Stockbridge, Georgia 30281
(770) 626-0177
Chicago, Illinois 60607
(312) 431-6780
Flossmoor, Illinois 60477
(708) 388-2245
Overland Park, Kansas 66212
(913) 381-7180
Overland Park, Kansas 66214
(913) 359-5699
Wichita, Kansas 67207
(316) 689-6635
Bardstown, Kentucky 40004
(502) 349-1569
Lexington, Kentucky 40509
(859) 264-8999
Lexington, Kentucky 45212
(513) 721-3868
Chalmette, Louisiana 70043
(504) 418-6040
New Orleans, Louisiana 70115
(504) 336-2667
Pikesville, Maryland 21208
(410) 602-1440
Boston, Massachusetts 02131
(843) 856-3784
Waltham, Massachusetts 02451
(781) 373-2940
Ann Arbor, Michigan 48104
(734) 677-6000
Minneapolis, Minnesota 55402
(612) 333-2200
Gulfport, Mississippi 39503
(228) 588-8268
Ridgeland, Mississippi 39157
(601) 790-1811
City of Saint Peters, Missouri 63303
(636) 387-5100
Hazelwood, Missouri 63042
(314) 972-9600
Kansas City, Missouri 64114
(816) 643-4153
Springfield, Missouri 65807
(417) 883-7889
St Louis, Missouri 63141
(314) 567-3377
Las Vegas, Nevada 89102
(702) 527-7401
Las Vegas, Nevada 89118
(702) 893-8968
Las Vegas, Nevada 89119
(702) 529-0153
Las Vegas, Nevada 89119
(702) 577-2000
North Las Vegas, Nevada 89030
(702) 637-3223
Reno, Nevada 89511
(775) 502-1616
Albuquerque, New Mexico 87102
(505) 224-7407
Amherst, New York 14226
(716) 250-2017
Brooklyn, New York 11235
(646) 747-4060
Commack, New York 11725
(631) 364-9119
New York, New York 10017
(212) 772-3570
Rochester, New York 14609
(585) 288-0890
Williamsville, New York 14221
(716) 626-6320
Charlotte, North Carolina 28277
(800) 785-3150
Greensboro, North Carolina 27405
(336) 516-9103
Greensboro, North Carolina 27405
(336) 574-8000
Raleigh, North Carolina 27607
(919) 800-5154
Shelby, North Carolina 28150
(704) 487-5228
Columbus, Ohio 43228
(614) 362-3980
Milford, Ohio 45150
(513) 831-5900
West Chester, Ohio 45069
(513) 646-4864
Edmond, Oklahoma 73034
(405) 285-6811
Oklahoma City, Oklahoma 73102
(405) 479-8331
Tulsa, Oklahoma 74133
(918) 932-2276
Yukon, Oklahoma 73099
(405) 281-3433
Portland, Oregon 97210
(855) 367-8834
Portland, Oregon 97223
(503) 610-0033
Allentown, Pennsylvania 18103
(818) 578-4555
Philadelphia, Pennsylvania 19114
(215) 676-6696
Pittsburgh, Pennsylvania 15236
(412) 650-6155
Scottdale, Pennsylvania 15683
(724) 220-5281
Smithfield, Pennsylvania 15478
(724) 569-8036
North Charleston, South Carolina 29405
(843) 856-3784
Chattanooga, Tennessee 37421
(423) 698-4584
Nashville, Tennessee 37203
(615) 320-6076
Nashville, Tennessee 37203
(615) 329-0197
Austin, Texas 78731
(512) 380-9925
Austin, Texas 78745
(512) 859-3834
Cypress, Texas 77372
(281) 315-4986
Cypress, Texas 77429
(949) 491-0710
Dallas, Texas 75251
(214) 361-7700
Houston, Texas 77024
(832) 203-7026
Houston, Texas 77081
(346) 550-9559
Lampasas, Texas 76550
(512) 556-4130
Plano, Texas 75093
(214) 856-2778
Waxahachie, Texas 75165
(972) 937-1640
Bountiful, Utah 84010
(385) 281-0550
Draper, Utah 84020
(801) 365-1032
Ogden, Utah 84405
(801) 409-2040
Riverton, Utah 84096
(801) 302-1769
Salt Lake City, Utah 84109
(801) 486-3021
Salt Lake City, Utah 84121
(801) 365-1032
Newport News, Virginia 23606
(757) 591-8100
Norfolk, Virginia 23502
(757) 614-1001
Seattle, Washington 98104
(206) 522-3330
Morgantown, West Virginia 26505
(304) 241-1648
Kenosha, Wisconsin 53144
(847) 406-8080
More Details
- Status
- Recruiting
- Sponsor
- Kallyope Inc.